Liquidia (NASDAQ: LQDA) announced it will present four poster sessions at the Pulmonary Hypertension Association's 2026 International PH Conference and Scientific Sessions in Dallas, with a featured poster highlighting patient-reported cough outcomes from its ASCENT clinical trial program. The presentations underscore the company's ongoing effort to generate peer-reviewed evidence across its inhaled-treprostinil platform.
The ASCENT cough-outcomes data is among the most operator-relevant disclosures on the docket, as tolerability endpoints — including treatment-emergent cough — remain a key clinical differentiator in the inhaled-therapy space. Patient-reported outcome instruments used in the ASCENT program capture symptom burden in a double-blind, placebo-controlled design, offering a structured look at real-world tolerability signals that prescribers and payers increasingly require before formulary acceptance.
While Liquidia's core platform sits squarely in specialty pharmaceutical territory rather than the dietary supplement or functional food channel, the conference context is relevant to nutraceutical formulators tracking inhaled and pulmonary-delivery bioavailability science. Advances in particle-engineering and dry-powder inhalation — the backbone of Liquidia's PRINT technology — are informing next-generation delivery formats for botanical extracts, adaptogens, and other bioactive compounds where oral bioavailability is a persistent formulation challenge. Suppliers and co-manufacturing partners developing inhalable or aerosolized nutraceutical formats are watching this space closely.
The PHA International Conference draws a global clinical and research audience, and poster sessions typically feed directly into peer-reviewed publication pipelines. For finished-formulation developers, data presented at specialty medical meetings can establish mechanism-of-action credibility that eventually supports structure-function claim development for adjacent consumer wellness applications. The broader pulmonary health category — encompassing supplements marketed for respiratory support, including NAC, quercetin, and magnesium — has seen sustained retail interest in the post-pandemic period.
Liquidia has not announced commercial nutraceutical partnerships, and the PHA presentations are clinical in scope. Operators in the functional foods and supplement channel should monitor whether the ASCENT tolerability dataset and associated delivery-science disclosures generate downstream licensing or white-label interest in precision-inhalation formats. Coverage of inhaled and alternative-delivery bioavailability research continues to expand across the respiratory health and delivery innovation beat, with growing crossover into clinical-evidence standards for structure-function claims.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.